Drugs / Cellgram-CKD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05042206 | Nov 2021 → Sep 2023 | chronic kidney disease | Pharmicell Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellgram-CKD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042206 ↗ |
| Modality | Cell therapy | “Allogeneic bone marrow-derived mesenchymal stem cell therapy” NCT05042206 ↗ |
| Route | Intravenous | “injected intravenously” NCT05042206 ↗ |